Background: Pain and osteoporosis are common in Parkinson's disease (PD), and lower bone mineral density (BMD) or osteoporosis may be associated with an increased risk of reporting to have pain in the general population. The aim of this study was to determine whether there is an association between the pain subtypes and the BMD in patients with PD. Methods: We included 162 PD patients. Pain was assessed using the patients' descriptions, a structured interview, a detailed neurologic examination, and the Visual Analogue Scale. BMD was measured using dual energy X-ray absorptiometry scans. Results: Of the 162 PD patients, 120 had chronic pain, while 42 reported no pain. The most prevalent type of pain was musculoskeletal, followed by radicular/neuropathic, dystonic, and central. PD patients with musculoskeletal pain had a lower BMD than PD patients without pain. Multivariate regression analysis showed that the low BMD of the lumbar spine, hip, and femoral neck were related to old age, female gender, low MBI, and the presence of musculoskeletal pain. Conclusion: PD patients with musculoskeletal pain have low BMD and are at risk for developing osteoporosis. If a PD patient has musculoskeletal pain and other risk factors related to low BMD, clinicians should consider screening for osteoporosis.

Keywords:
Pain, Musculoskeletal pain, Bone mineral density, Parkinson’s disease, Osteoporosis
1.
Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M: Pain is common in Parkinson's disease. Clin Neurol Neurosurg 2011;113:11-13.
2.
Ford B: Pain in Parkinson's disease. Mov Disord 2010;25(suppl 1):S98-S103.
3.
Beiske AG, Loge JH, Rønningen A, Svensson E: Pain in Parkinson's disease: prevalence and characteristics. Pain 2009;141:173-177.
4.
Roh JH, Kim BJ, Jang JH, Seo WK, Lee SH, Kim JH, et al: The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. Acta Neurol Scand 2009;119:397-403.
5.
Daniel SK, Lansang MC, Okun MS: Bone mineral density (BMD) in male patients with Parkinson's disease. Int J Neurosci 2012;122:523-527.
6.
Invernizzi M, Carda S, Viscontini GS, Cisari C: Osteoporosis in Parkinson's disease. Parkinsonism Relat Disord 2009;15:339-346.
7.
Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group: Association between Parkinson's disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 2005;53:1559-1564.
8.
Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR; Study of Osteoporotic Fractures (SOF) Research Group: The association of Parkinson's disease with bone mineral density and fracture in older women. Osteoporos Int 2008;19:1093-1097.
9.
van den Bos F, Speelman AD, van Nimwegen M, van der Schouw YT, Backx FJ, Bloem BR, et al: Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol 2013;260:754-760.
10.
Torsney KM, Noyce AJ, Doherty KM, Bestwick JP, Dobson R, Lees AJ: Bone health in Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014;85:1159-1166.
11.
Chou YC, Shih CC, Lin JG, Chen TL, Liao CC: Low back pain associated with sociodemographic factors, lifestyle and osteoporosis: a population-based study. J Rehabil Med 2013;45:76-80.
12.
Fernández-de-las-Peñas C, Hernández-Barrera V, Alonso-Blanco C, Palacios-Ceña D, Carrasco-Garrido P, Jiménez-Sánchez S, et al: Prevalence of neck and low back pain in community-dwelling adults in Spain: a population-based national study. Spine (Phila Pa 1976) 2011;36:E213-E219.
13.
Kim TH, Lee BH, Lee HM, Lee SH, Park JO, Kim HS, et al: Prevalence of vitamin D deficiency in patients with lumbar spinal stenosis and its relationship with pain. Pain Physician 2013;16:165-176.
14.
Hoozemans MJ, Koppes LL, Twisk JW, van dieen JH: Lumbar bone mass predicts low back pain in males. Spine (Phila Pa 1976) 2012;37:1579-1585.
15.
Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986;3:S1-S226.
16.
Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17.
Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, et al: Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology 2004;66:439-444.
18.
Huskisson EC: Visual analogue scales; in Melzack R (ed): Pain Measurement and Assessment. New York, Raven Press, 1983, pp 33-37.
19.
Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
20.
Fahn S, Elton R, Marsden C: Unified Parkinson's disease rating scale; in Fahn S, Marsden C, Goldstein M, Calne D (eds): Recent Developments in Parkinson's Disease. McMillan Healthcare Information. New Jersey, Florham Park, 1987, pp 153-163.
21.
Beck AT, Beamesderfer A: Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7:151-169.
22.
Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ: Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 2006;21:668-672.
23.
Ott SM, O'Hanlan M, Lipkin EW, Newell-Morris L: Evaluation of vertebral volumetric vs. areal bone mineral density during growth. Bone 1997;20:553-556.
24.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
25.
Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, et al: Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 2008;65:1191-1194.
26.
Lee MA, Walker RW, Hildreth TJ, Prentice WM: A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage 2006;32:462-469.
27.
Abou-Raya S, Helmii M, Abou-Raya A: Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing 2009;38:675-680.
28.
Wood B, Walker R: Osteoporosis in Parkinson's disease. Mov Disord 2005;20:1636-1640.
29.
Lee KM, Chung CY, Kwon SS, Kim TG, Lee IH, Jung KJ, et al: Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years. Clin Rheumatol 2015;34:337-343.
30.
Pongchaiyakul C, Nguyen ND, Jones G, Center JR, Eisman JA, Nguyen TV: Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 2005;20:1349-1355.
31.
Verstraeten A, van Ermen H, Haghebaert G, Nijs J, Geusens P, Dequeker J: Osteoarthrosis retards the development of osteoporosis. Observation of the coexistence of osteoarthrosis and osteoporosis. Clin Orthop Relat Res 1991;264:169-177.
32.
Dequeker J, Johnell O: Osteoarthritis protects against femoral neck fracture: the MEDOS study experience. Bone 1993;14(suppl 1):S51-S56.
33.
Tarantino U, Celi M, Rao C, Feola M, Cerocchi I, Gasbarra E, et al: Hip osteoarthritis and osteoporosis: clinical and histomorphometric considerations. Int J Endocrinol 2014;2014:372021.
34.
De Pedro JA, Martin AP, Blanco JF, Salvado M, Perez MA, Cardoso A, et al: Histomorphometric study of femoral heads in hip osteoarthritis and osteoporosis. Histol Histopathol 2007;22:1091-1097.
35.
Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP: Radicular and nonradicular back pain in Parkinson's disease: a controlled study. Mov Disord 2007;22:853-856.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.